阿霉素—转铁蛋白受体单抗偶联物对人肝细胞癌导向治疗的实验研究

SUPPRESSION OF HUMAN HEPATOCELLULAR CARCINOMA GROWTH IN NUDE MICE BY AN ANTI-TRANSEERRIN RECEPTOR-ADRIAMYCIN CONJUGATE

以ＤｅｘｔｒａｎＴ１０为偶联剂，将阿霉素与抗转铁蛋白受体单抗ＷｕＴ９交联，以此偶联物及对照制剂分别用于荷人肝细胞癌裸鼠的实验治疗。结果表明，无论从潜伏期还是从肿瘤生长速度比较，导向治疗组均优于各对照组。此外，各组荷瘤鼠ＮＫ细胞活性测定表明，导向制剂对宿主免疫机能的抑制作用最小。提示：阿霉素─转铁蛋白受体单抗偶联物可用于人肝细胞癌的生物导向治疗。

Conjugate of adriamycin and anti-transferrin receptor monoclonal antibody WuT9,was prepared using 30% oxidized Dextran T10 as a bridge and proved to retain both drug cytotoxity and antibody activity in vitro.The conjugate and its individual component were administered to athymic mice bearing human hepatoma cell line. Geometrical mean diameters (GMD) of tumors were measured daily. Statistically,the conjugate treat-ment was much better than all other agents in evaluating tumor GMD,latent period and growth speed. Fur-thermore,natural killer activity of spleen lymphocytes was measured by LDH releasing assay. The results showed that natural killer activity in conjugate treated group was much higher than those in other groups.we conclude that antitransferrin receptor-adriamycin conjugate may be used as a specific cytotoxic agent against human hepatocellular carcinoma.